- Home
- NEGG vs ELDN Comparison
NEGG vs ELDN Comparison
Compare NEGG & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- ELDN
- Stock Information
- Founded
- NEGG 2001
- ELDN 2004
- Country
- NEGG United States
- ELDN United States
- Employees
- NEGG N/A
- ELDN N/A
- Industry
- NEGG Other Specialty Stores
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- ELDN Health Care
- Exchange
- NEGG Nasdaq
- ELDN Nasdaq
- Market Cap
- NEGG 293.6M
- ELDN 239.6M
- IPO Year
- NEGG 2010
- ELDN N/A
- Fundamental
- Price
- NEGG $0.48
- ELDN $4.22
- Analyst Decision
- NEGG
- ELDN Strong Buy
- Analyst Count
- NEGG 0
- ELDN 1
- Target Price
- NEGG N/A
- ELDN $16.00
- AVG Volume (30 Days)
- NEGG 719.2K
- ELDN 414.7K
- Earning Date
- NEGG 12-31-2024
- ELDN 11-12-2024
- Dividend Yield
- NEGG N/A
- ELDN N/A
- EPS Growth
- NEGG N/A
- ELDN N/A
- EPS
- NEGG N/A
- ELDN N/A
- Revenue
- NEGG $1,391,833,000.00
- ELDN N/A
- Revenue This Year
- NEGG $6.01
- ELDN N/A
- Revenue Next Year
- NEGG N/A
- ELDN N/A
- P/E Ratio
- NEGG N/A
- ELDN N/A
- Revenue Growth
- NEGG N/A
- ELDN N/A
- 52 Week Low
- NEGG $0.44
- ELDN $1.43
- 52 Week High
- NEGG $1.45
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- NEGG 32.35
- ELDN 50.60
- Support Level
- NEGG $0.43
- ELDN $4.32
- Resistance Level
- NEGG $0.66
- ELDN $4.76
- Average True Range (ATR)
- NEGG 0.04
- ELDN 0.40
- MACD
- NEGG -0.01
- ELDN -0.05
- Stochastic Oscillator
- NEGG 22.96
- ELDN 26.06
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.